article · Drug Healthcare and Patient Safety

Adverse Events Following Immunization with Novel Oral Polio Vaccine Type 2, and the Experience and Challenges of Reporting in Sierra Leone

Fawzi Thomas
Onome T. Abiri
Desmond Kangbai
Edna G Samuels
Joyce M Kallon
Thomas Conteh
Sally-Mattu Conteh
Olufunsho Awodele

20245 citationsOpen accessUniversity of Lagos

Abstract

While the nOPV2 is relatively new, the majority of AEFI were not serious, and most serious cases were not causally linked to the vaccine. Participants exhibited variations in experience and awareness of AEFI reporting.

Research topics

Vaccine Coverage and Hesitancy
SARS-CoV-2 and COVID-19 Research
Pharmacovigilance and Adverse Drug Reactions

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.2147/dhps.s466039

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.